{"filing":{"accession_number":"0001104659-26-066575","cik":"0001974640","ticker":"APGE","company_name":"Apogee Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"tm2615568d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926066575/tm2615568d2_8k.htm"},"events":[{"id":8661,"run_id":7605,"accession_number":"0001104659-26-066575","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Apogee entered into a material definitive agreement with Blackstone Life Sciences on May 26, 2026, under which BXLS purchased revenue participation rights in zumilokibart (APG777) in exchange for up to $650 million in staged funding. This material financing and revenue-sharing arrangement affects the company's capital structure and future cash flows.","company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":1795,"accession_number":"0001104659-26-066575","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Apogee entered into a material definitive agreement with Blackstone Life Sciences on May 26, 2026, under which BXLS purchased revenue participation rights in zumilokibart (APG777) in exchange for up to $650 million in staged funding ($100M upfront, $100M on Phase 3 enrollment, $200M on positive Phase 3 data, and $250–$400M on FDA approval). This is a material financing and revenue-sharing arrangement that affects the company's capital structure and future cash flows, disclosed under Item 1.01 as a material definitive agreement. While not a traditional M\u0026A transaction, it represents a significant material transaction that would affect a reasonable investor's assessment of the registrant's financial position and product commercialization strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:34.736582+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1796,"accession_number":"0001104659-26-066575","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses entry into a \"Revenue Share Agreement\" (referenced in Item 1.01) and removal of cash runway end date guidance, signaling a material financing or strategic transaction. However, the Item 7.01 section itself provides minimal detail—the substance is cross-referenced to Item 1.01. Without the full Item 1.01 disclosure, the precise event type (ma_activity, dilutive_issuance, or other) cannot be definitively determined, warranting classification as other_material with moderate confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:34.736582+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1795,"accession_number":"0001104659-26-066575","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Apogee entered into a material definitive agreement with Blackstone Life Sciences on May 26, 2026, under which BXLS purchased revenue participation rights in zumilokibart (APG777) in exchange for up to $650 million in staged funding ($100M upfront, $100M on Phase 3 enrollment, $200M on positive Phase 3 data, and $250–$400M on FDA approval). This is a material financing and revenue-sharing arrangement that affects the company's capital structure and future cash flows, disclosed under Item 1.01 as a material definitive agreement. While not a traditional M\u0026A transaction, it represents a significant material transaction that would affect a reasonable investor's assessment of the registrant's financial position and product commercialization strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:34.736582+00:00","company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","filing_date":"2026-05-27"},{"id":1796,"accession_number":"0001104659-26-066575","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses entry into a \"Revenue Share Agreement\" (referenced in Item 1.01) and removal of cash runway end date guidance, signaling a material financing or strategic transaction. However, the Item 7.01 section itself provides minimal detail—the substance is cross-referenced to Item 1.01. Without the full Item 1.01 disclosure, the precise event type (ma_activity, dilutive_issuance, or other) cannot be definitively determined, warranting classification as other_material with moderate confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:34.736582+00:00","company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","filing_date":"2026-05-27"}]}